{"filings":[{"id":1194756,"accession_number":"0001104659-26-076364","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-06-22T20:05:23+00:00","items":["5.07"],"status":"ready","headline":"Cypherpunk Technologies 2026 annual meeting results: directors elected, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Will McEvoy and Nissim Mashiach elected as Class III directors with 24.9M and 22.2M votes for, respectively.","Advisory say-on-pay resolution passed with 20.7M votes for, 4.3M against, and 658.6K abstentions.","Ratification of EisnerAmper LLP as independent auditor for FY 2026 approved with 51.7M votes for.","Broker non-votes totaled 27.7M on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649805,"accession_number":"0001104659-26-066019","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-05-26T12:00:18+00:00","items":["8.01"],"status":"ready","headline":"Cypherpunk regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 21, 2026 confirming compliance with Listing Rule 5550(a)(2).","Previously disclosed deficiency on March 4, 2026 due to closing bid price below $1.00 for 30 consecutive days.","Nasdaq has closed the matter; company avoids delisting risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77522,"accession_number":"0001104659-26-060686","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-05-14T11:10:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cypherpunk Q1 net loss $77.2M as $77.6M unrealized ZEC loss hits earnings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $77.2M vs $15.4M YoY; $77.6M unrealized loss on ZEC marked to market.","ZEC price fell from $508.09 to $240.47 in Q1; ZEC holdings valued at $73.8M on March 31.","ZEC treasury increased to 314,185.70 ZEC (1.88% of circulating supply), avg cost $337.86.","Invested $5M into Zcash Open Development Labs (ZODL) alongside a16z, Coinbase, Paradigm.","FDA granted Fast Track designation for sirexatamab in DKK1-high metastatic colorectal cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93291,"accession_number":"0001104659-26-041981","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Four directors to retire from Cypherpunk board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Drs. Mirabelli, Loscalzo, Schilsky, and Cavanaugh resign effective immediately before the 2026 Annual Meeting.","Mirabelli and Loscalzo were Class III directors; Schilsky and Cavanaugh were Class I directors.","None of the departures are due to any disagreement with the company on operations, policies, or practices.","No replacements announced; the Board thanked each director for their service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104784,"accession_number":"0001104659-26-028558","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cypherpunk reports FY2025 net income of $4.8M; ZEC treasury at $147.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $4.8M vs net loss of $67.8M in 2024; driven by $50.4M unrealized gain on ZEC holdings.","Cash $14.0M; ZEC treasury 294,743.10 ZEC (1.78% of supply) at avg cost $335.89, valued $147.4M at year-end.","Closed $58.88M private placement led by Winklevoss Capital in October 2025.","Invested $5M in ZODL, developer of Zodl Zcash wallet, alongside a16z, Coinbase, Paradigm.","Sirexatamab in DKK1-high CRC showed ORR 44% vs 15.8% control; mOS not reached vs 9.66 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104783,"accession_number":"0001104659-26-025194","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cypherpunk Technologies receives Nasdaq minimum bid price deficiency letter; must regain compliance by Aug 31, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Cypherpunk that its common stock closing bid price was below $1.00 for 30 consecutive business days.","Company has 180 days, until August 31, 2026, to regain compliance by maintaining $1.00 closing bid for 10 consecutive days.","If compliance not met, Cypherpunk may qualify for a second 180-day period if it meets other Nasdaq initial listing standards.","The notice does not currently affect listing or trading on the Nasdaq Capital Market.","Management is considering options including a reverse stock split to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121066,"accession_number":"0001104659-25-125224","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Cypherpunk grants 5.45M RSUs to consultant CoinXit; cancels prior award","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted 5,448,157 RSUs under 2025 Equity Incentive Plan; cancels prior 2,411,700 RSUs under 2022 Plan.","RSUs vest 12/36 on Oct 8, 2026, then 1/36 monthly, subject to continuous service.","Grant satisfies all remaining RSU obligations under November 2025 Consulting Agreement with CoinXit.","CoinXit's sole director Khing Oei serves as Chairman of the Board and is a Winklevoss Treasury designee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121065,"accession_number":"0001104659-25-125039","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cypherpunk buys additional 56,418 ZEC for ~$29M, total holdings reach 290,063 ZEC (1.76% of supply)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 56,418.09 ZEC at $514.02/ZEC for ~$29 million.","Total ZEC holdings now 290,062.67, acquired at cumulative avg $334.41/ZEC.","Holdings represent ~1.76% of total circulating Zcash network supply.","CIO confirms goal to accumulate 5% of Zcash network.","Acquisition follows prior strategic purchases over preceding months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121064,"accession_number":"0001104659-25-121566","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02","5.07","5.03","8.01","9.01"],"status":"ready","headline":"Cypherpunk Tech stockholders approve 2025 equity plan, charter amendment, reverse split; Nasdaq compliance regained","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2025 Equity Incentive Plan covering up to 31,454,785 shares of common stock.","Charter amendment increased authorized shares from 250M to 500M (490M common, 10M preferred).","Reverse stock split approved with 36,314,864 votes for, 4,935,206 against, 691,181 abstain.","Private placement issuance approved with 17,403,379 votes for, 1,361,238 against, 154,144 abstain.","Nasdaq notified company on Dec 11, 2025 that it regained compliance with minimum bid price rule (Listing Rule 5550(a)(2))."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121063,"accession_number":"0001104659-25-114435","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cypherpunk Technologies enters waiver agreement with Winklevoss Capital to free shares for $200M ATM program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cypherpunk Technologies (CYPH) signed a waiver agreement with Winklevoss Capital on November 19, 2025, modifying the October 8, 2025 common warrant.","Winklevoss waived the share reservation covenant for 57,182,378 warrant shares to allow their issuance under the company's $200 million ATM equity offering program.","Winklevoss cannot exercise the warrant for those restricted shares until authorized common stock reaches 490 million shares or a reverse stock split of at least 1:5 occurs.","The waiver applies only to the 57,182,378 restricted shares; other warrant shares remain unaffected.","The agreement supports Cypherpunk's ability to raise capital through its existing ATM facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121062,"accession_number":"0001104659-25-113698","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cypherpunk buys additional $18M of Zcash, now holds 1.43% of network","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 29,869.29 ZEC for $18M at average price $602.63/ZEC on November 18, 2025.","Total ZEC holdings now 233,644.56 at average cost $291.04, representing 1.43% of the Zcash network.","Initial acquisition of 203,775.27 ZEC for $50M at $245.37/ZEC was disclosed November 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121071,"accession_number":"0001104659-25-110341","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cypherpunk Technologies (fka Leap Therapeutics) enters up to $200M ATM equity sales agreement with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to sell up to $200M of common stock.","Cantor will receive a commission of up to 3.0% of gross proceeds from each sale.","Sales will be made 'at the market' under existing shelf registration statement (File No. 333-278015).","Company has no obligation to sell any shares and can suspend or terminate agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121070,"accession_number":"0001104659-25-109820","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.03","1.01","2.02","5.02","7.01","8.01"],"status":"ready","headline":"Leap Therapeutics rebrands as Cypherpunk, buys $50M ZEC, appoints new leaders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company renamed Cypherpunk Technologies; stock ticker changes from LPTX to CYPH on Nov 13, 2025.","Acquired 203,775 ZEC for $50M ($245.37 avg) under new digital-asset treasury strategy.","Khing Oei appointed Chairman; Will McEvoy appointed CIO and director; Oei's CoinXit Ltd. engaged as consultant.","Awarded 2,411,700 RSUs to CoinXit and 5,616,906 RSUs to McEvoy (subject to conditions), plus RSUs to directors/employees.","Reported Q3 2025 financial results (press release furnished as Exhibit 99.2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121069,"accession_number":"0001104659-25-100646","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Leap's sirexatamab shows statistically significant PFS/OS benefit in DKK1-high CRC at ESMO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In DKK1-high (upper median, n=88): mPFS 9.03 vs 7.06 mo (HR 0.61, p=0.0255); mOS not reached vs 14.39 mo (HR 0.42, p=0.0118).","In DKK1-high (upper quartile, n=44): mPFS 9.36 vs 5.88 mo (HR 0.46, p=0.017); mOS not reached vs 9.66 mo (HR 0.17, p<0.001).","Full ITT (n=188): mPFS 9.2 vs 8.3 mo (HR 0.84, p=0.171); ORR 35.1% vs 26.6%.","Sirexatamab well tolerated; TEAE profile similar between arms.","Leap plans to engage regulators on registrational path for sirexatamab in CRC; supported by recent financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121068,"accession_number":"0001104659-25-098082","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","3.02","7.01","8.01"],"status":"ready","headline":"Leap Therapeutics closes $58.9M private placement led by Winklevoss Capital to pursue digital asset treasury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$58.88M from sale of 15.2M shares, 80.8M pre-funded warrants, and 72.0M common warrants.","Winklevoss Capital leads the deal; gets right to nominate two board members, one of whom will serve as chair.","Proceeds to fund a digital asset treasury strategy and continue development of FL-501 and sirexatamab.","Common warrants priced at $0.5335/share, 10-year term; pre-funded warrants exercisable at $0.001/share with no expiration.","Parcrest serves as placement agent; receives $1.5M fee ($1M cash plus warrants for 4M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121067,"accession_number":"0001104659-25-096966","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Leap Therapeutics raises $58.9M in PIPE led by Winklevoss Capital, adopts digital asset treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$58,888,888 in cash commitments for PIPE offering at $0.61439 per unit, led by Winklevoss Capital.","Issues 95.8M shares/pre-funded warrants and 71.9M warrants exercisable at $0.5335 per share.","Closing expected October 8, 2025; Winklevoss Capital to nominate two board members, one as chair.","Proceeds to fund digital asset treasury strategy and continued development of FL-501 and sirexatamab.","Company reaffirms pursuit of existing biotech pipeline alongside new digital asset strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137692,"accession_number":"0001410578-25-002072","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Leap Therapeutics gets Nasdaq bid price extension to March 9, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted additional 180-day compliance period until March 9, 2026, for minimum $1.00 bid price.","Initial 180-day period ended Sept. 8, 2025; company met all other listing standards except bid price.","Company may implement a reverse stock split to regain compliance.","No assurance of regaining compliance; delisting could follow if not cured by March 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137691,"accession_number":"0001104659-25-078077","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q2 net loss $16.6M, cuts workforce 75%, explores strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.6M for Q2 2025 vs $20.4M in Q2 2024; cash and equivalents $18.1M at June 30, 2025.","R&D expenses $10.5M (down from $17.9M); G&A $1.8M (down from $3.4M); restructuring charge $4.5M.","Board initiated review of strategic alternatives; engaged Raymond James as financial advisor.","Workforce reduced ~75% to preserve capital; majority of severance costs in Q3/Q4 2025.","Updated Phase 2 DeFianCe data showed statistically significant benefit on ORR and PFS in certain CRC subgroups."],"consensus_eps_estimate":-0.2958,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155075,"accession_number":"0001104659-25-061385","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["2.05","5.02","5.07","8.01","9.01"],"status":"ready","headline":"Leap reports sirexatamab PFS benefit in CRC subgroups; workforce cut 75%, strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DeFianCe study: in high-DKK1 pts (upper quartile), median PFS 9.36 vs 5.88 mo (HR 0.47, p=0.024); ORR 44% vs 15.8% (p=0.015).","VEGF-naïve pts: median PFS 11.2 vs 8.34 mo (HR 0.61, p=0.038); ORR 55.1% vs 32.6% (p=0.012).","Full population ORR by BICR 33% vs 20.2% (p=0.0203); median PFS 9.2 vs 8.31 mo (HR 0.84, p=0.1749) not significant.","Board initiates strategic alternatives review; Raymond James engaged as advisor; workforce reduction of ~75% with $3.2M severance costs.","COO (Lawlor) terminated June 30, CMO (Sirard) terminated July 31; cash $32.7M (Mar 31)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155074,"accession_number":"0001104659-25-047564","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q1 net loss $15.4M; workforce cut ~50%; sirexatamab shows positive Phase 2 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.4M in Q1 2025 vs $13.8M in Q1 2024; R&D expense rose to $12.9M.","Cash and equivalents $32.7M at March 31, 2025.","Positive DeFianCe study data: 32% higher ORR and 3.5-month PFS benefit in DKK1-high CRC patients.","Strategic restructuring reduced workforce by ~50% to prioritize sirexatamab and FL-501.","Engaged financial advisor to explore business development for sirexatamab registrational Phase 3."],"consensus_eps_estimate":-0.3876,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173591,"accession_number":"0001104659-25-028015","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Leap reports positive sirexatamab CRC data: 32% higher ORR, 3.5mo PFS in high DKK1 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["High DKK1 patients: sirexatamab arm ORR 48% vs 15.8% control; median PFS 9.36 vs 5.88 mo (HR 0.46); OS HR 0.09.","No prior anti-VEGF patients: ORR 55.1% vs 32.6%; median PFS 10.94 vs 8.34 mo (HR 0.59); OS immature.","FY2024 net loss $67.6M ($81.4M in 2023); R&D expenses $57.2M ($73.2M in 2023).","Cash and equivalents $47.2M at Dec 31, 2024; engaged financial advisor for business development.","FL-501 abstract accepted at AACR 2025; preclinical data to be presented April 25-30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173590,"accession_number":"0001104659-25-024450","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Leap Therapeutics receives Nasdaq deficiency notice for low bid price; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days as of March 12, 2025.","Company has until September 8, 2025 to regain compliance by closing at $1.00 for at least 10 consecutive days.","Potential for additional 180-day compliance period if other listing standards met.","Company reviewing options; no assurance of regaining compliance.","Notice is a deficiency, not delisting; shares continue to trade on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173589,"accession_number":"0001104659-25-006544","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sirexatamab + chemo/bev shows 35% ORR in CRC (vs 23% control); gastric trial fails to advance to Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part B DeFianCe (n=188): sirexatamab arm ORR 35% vs control 23%; DCR 86% vs 84%.","Left-sided tumors ORR 38% (experimental) vs 25% (control); DKK1-high upper quartile ORR 48% vs 11%.","PFS not yet mature; 82 patients still on study. Leap plans registrational Phase 3 in CRC subject to regulatory discussions.","Part C DisTinGuish gastric: no clear positive signal; primary PFS endpoints will be negative; no Phase 3 plans for gastric.","Gastric study showed high discordance between investigator and BICR; sirexatamab combo well-tolerated in both studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190568,"accession_number":"0001104659-24-117217","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q3 net loss $18.2M; DKN-01 CRC enrollment complete, data mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.2M for Q3 2024, up from $13.7M YoY, driven by higher R&D expenses.","R&D expenses $14.9M (vs $11.5M); G&A $2.9M (vs $3.3M); cash $62.8M at Sept 30, 2024.","Completed enrollment (188 patients) in Part B of DeFianCe study (DKN-01 in CRC); initial data expected mid-2025.","DisTinGuish study (GEJ/gastric) Part C follow-up ongoing; initial data late 2024 or early 2025.","Initiated development of FL-501, an anti-GDF-15 antibody for cachexia; promising preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207063,"accession_number":"0001104659-24-103942","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics completes enrollment of 188 patients in Phase 2 DeFianCe study of DKN-01 for CRC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 188 patients in randomized controlled Part B of DeFianCe study (NCT05480306).","Evaluates DKN-01 + bevacizumab + chemo as second-line therapy for advanced colorectal cancer.","Primary endpoint: progression-free survival overall and in left-sided CRC subpopulation.","Initial data from Part B expected in mid-2025; Part A showed encouraging response rates.","Study expanded from 130 to 188 patients, reflecting investigator and patient interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207062,"accession_number":"0001104659-24-088051","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q2 net loss $20.4M; DKN-01 ORR 33% in CRC; $40M PIPE completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.4M in Q2 2024 vs $13.4M in Q2 2023; R&D expenses rose to $17.9M on trial costs.","DKN-01 combo achieved 33% ORR (38% left-sided) in Part A of DeFianCe CRC study; median PFS 6.3 months.","Enrollment in Part B expanded to 180 patients; completion expected Sept 2024, data mid-2025.","DisTinGuish Part C gastric/GEJ cancer data expected Q4 2024 or early 2025.","Completed $40M private placement with Gilead, Samsara, others; cash $78.5M funds into Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207061,"accession_number":"0001104659-24-078325","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Leap Therapeutics reports stockholder votes: directors elected, equity plan amended, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James Cavanaugh, Douglas Onsi, Christian Richard, and Richard Schilsky elected Class I directors with over 16.7 million votes each.","Advisory vote on executive compensation passed with 16,820,682 for, 1,272,059 against, 40,120 abstain.","Amendment to the 2022 Equity Incentive Plan approved with 16,572,103 for, 1,480,150 against, 80,608 abstain.","Ratification of EisnerAmper LLP as independent auditor for fiscal 2024 passed with 25,894,496 for, 71,613 against, 37,856 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224379,"accession_number":"0001104659-24-060199","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics reports Q1 2024 net loss of $13.8M; completes $40M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.8M for Q1 2024 vs $41.9M Q1 2023; decrease due to $29.6M IPR&D expense from Flame merger in prior year.","Completed $40M private placement with Gilead and other investors; net proceeds $37.2M extend cash runway into Q2 2026.","Expanded Part B of DeFianCe CRC study from 130 to 180 patients; enrollment expected late Q3/Q4 2024, data mid-2025.","Part C of DisTinGuish GEJ/gastric cancer study fully enrolled (170 patients); initial data expected H2 2024 or early 2025.","Cash and equivalents $54.9M at March 31, 2024; exclusive of April 2024 private placement proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224378,"accession_number":"0001104659-24-046108","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Leap Therapeutics raises $40M in private placement to fund DKN-01 clinical trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$40M from sale of 12.66M shares at $2.82 and pre-funded warrants for 1.52M shares at $2.819.","Financing expected to close April 15, 2024; investors include Gilead Sciences and other institutional investors.","Proceeds to expand DeFianCe colorectal cancer study from 130 to 180 patients and advance DisTinGuish gastric cancer study.","Cash runway extended into Q2 2026; funds also used for Phase 3 readiness manufacturing and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243695,"accession_number":"0001104659-24-035239","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics reports FY2023 net loss $81.4M; cash $70.6M; DKN-01 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $81.4M in FY2023 vs $54.6M in FY2022; R&D expenses $73.2M.","Cash and equivalents $70.6M at Dec 31, 2023; research incentive receivables $0.8M.","DeFianCe Part A (CRC): 30% ORR, 93% DCR; median PFS 6.3 months in 2L MSS CRC.","Completed enrollment (170 pts) in DisTinGuish Part C for gastric/GEJ cancer; data expected mid-2024.","Randomized Part B of DeFianCe (130 pts) enrolling; 80 enrolled as of Mar 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243694,"accession_number":"0001104659-24-005944","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics posts updated corporate presentation; no material specifics disclosed in filing text.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed Form 8-K on Jan 23, 2024, stating it posted an updated corporate presentation on its website.","Exhibit 99.1 contains the corporate presentation, but its content was not provided in the filing.","No financial results, pipeline updates, or other material information can be derived from the filing alone.","Investors should review the presentation directly on the company website for potential updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243693,"accession_number":"0001104659-24-004162","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics reports 30% ORR and 93% DCR in Part A of DeFianCe study for DKN-01 in second-line CRC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Across 27 evaluable microsatellite stable CRC patients: ORR 30%, DCR 93%, median PFS 6.3 months.","Left-sided tumors: 33% ORR, 100% DCR, preliminary median PFS 8.6 months.","Rectal/rectosigmoid subgroup (n=15): 46% ORR, 100% DCR, preliminary median PFS 9.4 months.","DKN-01 plus bevacizumab and chemotherapy well-tolerated; majority of related events Grade 1/2.","Part B of study enrolling well, expected to complete enrollment mid-2024; conference call January 23."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261095,"accession_number":"0001104659-23-125356","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Leap Therapeutics sells IL-1ß antibody assets to AlmataBio for $500K cash plus up to $70M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into Asset Purchase Agreement with AlmataBio for IL-1ß antibodies FL-101 and FL-103.","Received $500,000 cash at closing; potential milestone payments up to $70 million tied to regulatory and sales milestones.","Buyer assumed all liabilities related to the transferred assets.","80% of after-tax net proceeds from sale to be paid to former Flame Biosciences equityholders as additional merger consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261094,"accession_number":"0001104659-23-116657","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q3 net loss $13.7M; DKN-01 colorectal study expands to Part B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M in Q3 2023 vs $15.1M in Q3 2022; cash and equivalents $80.7M.","DKN-01 DeFianCe Part A met >20% ORR threshold; Part B with 130 patients now enrolling; data at Jan 2024 med conf.","DisTinGuish gastric cancer Part C enrollment expected by end 2023; prior data showed 73% ORR, 19.5 mo OS.","R&D expenses $11.5M vs $12.1M; G&A $3.3M vs $3.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278367,"accession_number":"0001104659-23-100396","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics posts updated corporate presentation; no specifics in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an 8-K on Sept 13, 2023, announcing an updated corporate presentation on www.leaptx.com.","Exhibit 99.1 is the presentation, but no substantive content was included in the filing text.","No financial results, pipeline milestones, or other material updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278366,"accession_number":"0001104659-23-090875","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q2 net loss $13.4M; DKN-01 CRC trial advances to Part B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.4M in Q2 2023 vs $17.0M in Q2 2022; R&D expenses fell to $11.1M.","Cash and equivalents $91.4M at June 30, 2023; interest income $1.2M.","DeFianCe Part A CRC study achieved >20% ORR; 130-patient randomized Part B initiated.","DisTinGuish GEA data: 73% ORR (mITT), median OS 19.5 months, median PFS 11.3 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278365,"accession_number":"0001104659-23-080168","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics starts randomized Part B of DKN-01 Phase 2 CRC study after positive Part A","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated 130-patient randomized controlled Part B of DeFianCe study of DKN-01 in second-line advanced colorectal cancer.","Part A enrolled 33 aggressive CRC patients and exceeded 20% overall response rate, triggering Part B.","Primary endpoint of Part B is progression-free survival; enrollment expected ~12 months, data late 2024.","Regained Nasdaq compliance with minimum bid price rule after 11 consecutive days above $1.00 (July 6, 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296518,"accession_number":"0001104659-23-073405","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Leap Therapeutics shareholders approve reverse split, equity plan; preferred converts to 24M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Loscalzo, Mashiach, Mirabelli elected as Class III directors at annual meeting.","Advisory vote on executive compensation approved; frequency set to annual until 2029.","Amendment to 2022 Equity Incentive Plan and reverse stock split approved by shareholders.","Series X Non-Voting Convertible Preferred Stock conversion effective June 21, after approval.","Post-conversion and reverse split, common shares outstanding: 24,005,499."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296517,"accession_number":"0001104659-23-072982","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics effecting 10-for-1 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio of 10-for-1, effective 5PM ET on June 20, 2023.","Common stock to trade on split-adjusted basis under \"LPTX\" on Nasdaq starting June 21, 2023.","Split approved by stockholders on June 16, 2023; board set final ratio.","Purpose: increase per-share price to meet Nasdaq minimum bid requirement and facilitate Series X preferred conversion.","No fractional shares issued; cash paid in lieu; all equity awards and warrants adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296516,"accession_number":"0001104659-23-064739","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics reports 19.5-month median OS from DKN-01 combo in gastric cancer; data at ASCO 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 19.5 months, median PFS 11.3 months in first-line GEA patients (n=25), exceeding current benchmarks.","ORR 73% in mITT population; 86% ORR in PD-L1-low patients; 90% ORR in DKK1-high patients.","Additional partial response after 22 months of therapy; tumor reductions deepen over time.","Part C randomized controlled trial enrolling; completion expected late 2023; colorectal data coming."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296515,"accession_number":"0001104659-23-060130","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q1 net loss $41.9M on $29.6M IPR&D charge; cash $102M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.9M ($10.4M Q1'22); includes $29.6M IPR&D charge from Flame acquisition.","R&D expense $38.9M, G&A $3.8M; cash $102.0M at Mar 31, 2023.","Completed Part A enrollment in Phase 2 DeFianCe study of DKN-01 in CRC; initial data mid-2023.","Acquired Flame Biosciences, adding anti-Claudin18.2 candidate FL-301 and ~$50M cash.","Will present updated long-term data from DisTinGuish study in GEA at ASCO June 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296514,"accession_number":"0001104659-23-050363","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics to present updated DKN-01/Gastric Cancer data at ASCO 2023","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Will present long-term follow-up data from Part A of Phase 2 DisTinGuish study at ASCO June 2-6, 2023.","Presentation scheduled for June 5, 2023, at 11:30 a.m. ET; abstract #4027, poster discussion session.","Study combines DKN-01 (anti-DKK1) + tislelizumab + chemo in first-line advanced GEA; Part A enrolled 25 pts.","Ongoing Part C enrolling ~160 first-line HER2- GEA pts in randomized controlled trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296513,"accession_number":"0001104659-23-044293","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics completes Part A enrollment (33 pts) in Phase 2 DeFianCe study of DKN-01 for colorectal cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part A enrolled 33 patients with advanced colorectal cancer; study is randomized, open-label, multicenter.","Part B is planned as a 130-patient randomized controlled trial; primary endpoint is progression-free survival.","Initial data from the study expected in mid-2023.","Secondary endpoints include overall response rate, duration of response, and overall survival."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296512,"accession_number":"0001104659-23-043095","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Leap Therapeutics amends CMO's severance; boosts benefits post-change-in-control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CMO Cynthia Sirard gets 100% base salary severance (12 monthly installments) on non-Cause termination or Good Reason resignation.","Post-change-in-control termination within 1 year: severance increases to 125% base salary (lump sum) and COBRA reimbursed for 15 months (lump sum).","Equity awards become exercisable for up to 2 years after qualifying termination following a change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316953,"accession_number":"0001104659-23-036246","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics FY2022 net loss $54.6M; cash $65.5M plus $50M from Flame acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.6M for 2022 (vs $40.6M in 2021); R&D expenses $45M (vs $32.2M).","Cash $65.5M at Dec 31, 2022; excludes ~$50M cash from Flame acquisition in Jan 2023.","Flame acquisition: issued ~19.8M common shares + 136.8k preferred convertible into 136.8M common shares (subject to approval).","DKN-01: Part C DisTinGuish randomized trial enrollment expected completion late 2023; Part A DeFianCe CRC study enrollment near completion.","BeiGene's option for DKN-01 in Asia expired; clinical collaboration continues for DisTinGuish Part C."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316949,"accession_number":"0001104659-23-036607","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K/A","filed_at":"2023-03-24T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Leap Therapeutics removes requirement to file Flame Biosciences financials","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to 8-K (filed Jan 23, 2023) deletes references to filing financial statements and pro forma info for Flame Biosciences acquisition.","Company determined financial statements for the January 2023 acquisition are not required under Item 9.01 of Form 8-K.","No change to acquisition terms or closing date; procedural update only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316952,"accession_number":"0001104659-23-033314","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["1.01","5.03","5.07","8.01","9.01"],"status":"ready","headline":"BeiGene option for DKN-01 expired; Leap retains global rights, continues clinical collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BeiGene's option to license DKN-01 in Asian territories expired; Leap retains global rights.","Collaboration continues on Part C of DisTinGuish trial (DKN-01 + tislelizumab + chemo) in first-line gastric cancer; enrollment completion expected late 2023.","Cash runway extended into mid-2025 following Flame Biosciences acquisition; company seeking new strategic partner for DKN-01.","Company will also develop Claudin18.2 programs acquired from Flame as part of focus on GI cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316951,"accession_number":"0001104659-23-005803","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","5.02","9.01"],"status":"ready","headline":"Leap Therapeutics acquires Flame Biosciences in merger, issuing ~19.8M shares and Series X Preferred","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Flame Biosciences for approx 19.8M common shares and 136,833 Series X Convertible Preferred shares.","Flame stock options cancelled; outstanding warrants assumed and converted into Leap warrants.","Appointed Patricia Martin and Christian Richard as new non-employee directors.","Will hold special stockholder meeting to approve conversion of Series X Preferred into common shares.","Entered into support agreements with HealthCare Ventures IX and HealthCare Ventures VIII."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316950,"accession_number":"0001104659-23-004066","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2023-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Leap Therapeutics acquires Flame Biosciences, gaining FL-301 and ~$50M net cash, combined cash ~$115M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Flame for ~19.8M shares common + ~136.8k Series X preferred (convertible to 1,000 common each).","Combined cash ~$115M (incl. ~$50M net from Flame) expected to fund operations to mid-2025.","Pipeline adds clinical anti-Claudin18.2 antibody FL-301 and preclinical FL-302/FL-501 programs.","Flame shareholders to own 58% of pro forma shares (as-converted), pending stockholder approval of conversion.","Board expanded to include Patricia Martin and Christian Richard; existing management remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335214,"accession_number":"0001104659-22-117681","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics reports Q3 2022 net loss of $15.1M, up from $11.1M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.1M in Q3 2022 vs $11.1M in Q3 2021; R&D expenses $12.1M.","Cash and equivalents $78.3M at Sept 30, 2022; plus $1.3M R&D incentive receivable.","Enrolled first patient in Part C of DisTinGuish study (GEA) and DeFianCe study (CRC).","Presented updated DKN-01 clinical data at ESMO and SITC meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":121369519.34579438,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-14T23:59:59+00:00|335214"}